Transaction DateRecipientSharesTypePriceValue
24th February 2021Michael J Brown2,249Payment by withholding$156.27$351,451.23
24th February 2021Michael J Brown7,236Grant/award etc.$0.00
1st January 2021Chandler Robinson2,327Payment by withholding$6.12$14,241.24
1st January 2021Chandler Robinson6,724Exercise of derivative$0.00
1st January 2021Kim R Tsuchimoto1,231Exercise of derivative$0.00
1st January 2021Andrew Paul Mazar1,937Exercise of derivative$0.00
1st January 2021Kim R Tsuchimoto504Payment by withholding$6.12$3,084.48
1st January 2021Andrew Paul Mazar671Payment by withholding$6.12$4,106.52
31st December 2020Michael J Brown322Exercise of derivative$0.00
31st December 2020Arthur J Klausner322Exercise of derivative$0.00
Monopar Therapeutics
Monopar Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.


Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014.


Ticker: MNPR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1645469
Employees: 7
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals